inclusion body myositis

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.inclusion body myositis - myositis characterized by weakness of limb muscles (especially the thighs and wrists and fingers); sometimes involves swallowing muscles; onset after 50 and slowly progressive; seen more often in men than in women
myositis - inflammation of muscle tissue
Mentioned in ?
References in periodicals archive ?
Global Markets Direct's, 'Inclusion Body Myositis (IBM) - Pipeline Review, H1 2016', provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape.
In April 2015, she presented with progressive weakness in her upper and lower extremities, with neurological testing and pathology consistent with inclusion body myositis.
Therefore, inclusion body myositis (IBM) would probably not find a place in this sub-classification.
USPRwire, Mon Nov 02 2015] Global Markets Direct's, 'Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015', provides an overview of the Inclusion Body Myositis (IBM)'s therapeutic pipeline.
Muscle biopsy of the left vastus medialis muscle revealed rimmed vacuoles in muscle fibers with necrosis, regeneration, and congophilic staining inclusions, consistent with a diagnosis of inclusion body myositis (IBM) (Figures 1 and 2).
The list of possible causes of these complaints can be lengthy and vary greatly, from nonmyopathic conditions such as fibromyalgia to worrisome forms of myopathy such as inclusion body myositis or polymyositis.
BYM338 is an investigational drug for the treatment of sporadic inclusion body myositis (sIBM), a rare disease yet the most common degenerative disease of muscle in adults older than 65 years.
The ultra-rare diseases category includes Duchenne's muscular dystrophy (DMD), molybdenum cofactor deficiency (MoDC) type A, lysosomal acid lipase (LAL) deficiency, sporadic inclusion body myositis (sIBM), epidermal bulbosa (EB), Lambert-Eaton myasthenic syndrome (LEMS) and hypothosphatasia.
Novartis has secured FDA breakthrough therapy designation for bimagrumab for sporadic inclusion body myositis in August 2013.
Last month Novartis AG announced that the FDA granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).
All older patients finally diagnosed as sporadic inclusion body myositis - showing as myalgias and muscle atrophy, unresponsive to steroids-improve with avoidance of gluten.